Treatment

Document Overview

Design and created by Guideline Central in participation with the American Thoracic Society.

Treatment Of Idiopathic Pulmonary Fibrosis

American Thoracic Society

Publication Date: Jul 1, 2015

Page Last Updated: May 5, 2026

Quality of the Evidence (GRADE) and Implications

Quality of Evidence	Symbol	Implications
High	⊕⊕⊕⊕	Further research is very unlikely to change confidence in the estimate of effect.
Moderate	⊕⊕⊕⊖	Further research is likely to have an important impact on confidence in the estimate of effect and may change the estimate.
Low	⊕⊕⊖⊖	Further research is very likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate.
Very low	⊕⊖⊖⊖	The guideline committee is very uncertain about the estimate.

The quality of the evidence is a judgment about the extent to which we can be confident that the estimates of effect are correct. These judgments are made for each outcome using the GRADE system. The judgments are based upon the study design (randomized trials, observational studies, or other), risk of bias, consistency of results across studies, and precision of the overall estimates across studies. For each outcome, the quality of the evidence is rated as high, moderate, low, or very low. (For more information about the GRADE system, see: www.gradeworkinggroup.org )

Document Overview

Document Title: Treatment Of Idiopathic Pulmonary Fibrosis

Authoring Society: American Thoracic Society

Document Publication Date: Jul 1, 2015

Page Last Reviewed/Updated: May 5, 2026

Document Type: Guideline

Country of Publication: United States

Full Text Freely Available: Yes

Full Text Guideline: www.atsjournals.org/doi/full/10.1164/rccm.201506-1063ST

Supplemental Implementation Resources

Calculator

Document Scope, Criteria, and Use Cases

Document Objectives: This document updates the American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guideline on idiopathic pulmonary fibrosis treatment.

Scope: Management, Treatment

Diseases/Conditions (MeSH)

D054990 - Idiopathic Pulmonary Fibrosis

Keywords: ILD, IPF, Idiopathic pulmonary fibrosis (IPF), Pulmonary Fibrosis, interstitial lung disease

Target Patient Population: patients with idiopathic pulmonary fibrosis

Inclusion Criteria: Male, Female, Adult, Older Adult

Health Care Settings: Ambulatory

Intended Users: Nurse, Nurse Practitioner, Physician, Physician Assistant

Recommendation Development Processes & Methodology

Supplemental Methodology Resources: Data Supplement Data Supplement

Number of Source Documents: 105

Literature Search Start Date: Saturday, May 1, 2010

Literature Search End Date: Tuesday, July 1, 2014

Includes peer/external review process?: Yes

Includes public comment process?: No

Methodologist involvement?: Yes

Patient involvement?: No

Includes multi-disciplinary group?: Yes

Includes systematic review?: Yes

Grades quality of strength of evidence?: Yes

Grades quality of strength of recommendation?: Yes

Discloses funding source?: Yes

Discloses conflicts of interest?: Yes

Includes benefits/harms analysis with recommendations?: Yes

Treatment Of Idiopathic Pulmonary Fibrosis

Treatment

For patients with IPF, the guideline committee recommends:

For patients with IPF, the guideline committee suggests:

Quality of the Evidence (GRADE) and Implications

Document Overview

Supplemental Implementation Resources

Document Scope, Criteria, and Use Cases

Recommendation Development Processes & Methodology